In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Illumina buys Solexa in stock-for-stock transaction

Executive Summary

Expanding into next-generation sequencing, Illumina has agreed to acquire fellow genomics analysis company Solexa in a stock swap valued at $600mm, or about $14 per outstanding Solexa share (a 44% premium based on the 10-day pre-announcement average). Illumina will also buy $50mm in newly issued Solexa shares (5.15mm at the market price of $9.70).
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Nanotechnology, Chips, etc.
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies

UsernamePublicRestriction

Register